https://impactfactor.org/PDF/IJDDT/16/IJDDT,Vol16,Issue80s,Article43.pdf
Trigeminal neuralgia (TN) is a chronic neuropathic pain disorder characterized by recurrent, severe facial pain that significantly impairs quality of life. Conventional pharmacological agents, while effective, are often associated with dose-dependent side effects, reduced patient compliance, and poor long-term efficacy. Phytoconstituents with multimodal actions are gaining attention as safer alternatives. Butea monosperma, a medicinal plant known for its anti-inflammatory, antioxidant, and neuroprotective properties, has shown promise in alleviating neuropathic pain. However, its therapeutic application is hindered by poor solubility, low systemic bioavailability, and rapid metabolism. Nanocarrier-based drug delivery systems offer a viable strategy to overcome these limitations. Polyethylene glycol (PEG), a biocompatible and non-immunogenic polymer, provides advantages such as enhanced solubility, prolonged circulation time, and controlled release of encapsulated drugs. Development of a PEG-based nanocarrier for Butea monosperma aims to optimize its pharmacokinetics, ensure sustained therapeutic action, and minimize systemic toxicity in TN management. This novel approach integrates the therapeutic potential of phytomedicine with the precision of nanotechnology, offering a promising, patient-friendly, and effective alternative for the long-term management of trigeminal neuralgia.
Authors
- Selva Sigamani V
- Jayanth Kumar Vadive
Institutions
- Saveetha University (IN)
Publication Details
- Journal
- International Journal of Drug Delivery Technology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.25258/ijddt.16.80s.44
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00